6:32AM Pharmacyclics triggers another significant milestone payment for Phase III chronic lymphocytic leukemia combination trial (PCYC) 65.56 : Co announces that the international, randomized Phase III clinical trial of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a third $50 mln milestone payment obligation from Janssen Biotech, one of the Janssen Pharmaceutical Companies, worldwide collaborator on ibrutinib in oncology and sponsor of this CLL3001 trial.
Market Data 
Markets 
AI
